Vaccine

Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022

BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam…

3 years ago

Teknova Announces Early Access Program for Novel Products to Address Critical Pain Points in Gene Therapy Bioproduction

Company Also Announces New WFI Quality Water Product to be Made Available Through Online Catalog in NovemberHOLLISTER, Calif., Oct. 13,…

3 years ago

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE)…

3 years ago

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…

3 years ago

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

•  No safety concerns noted in ongoing clinical trial•  Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE…

3 years ago

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),…

3 years ago

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved TreatmentsPURCHASE, N.Y., Oct. 12, 2022 (GLOBE…

3 years ago

Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022…

3 years ago

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901…

3 years ago